Business
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
A non-interventional study published in Frontiers in PsychiatryPsychometric profile characterization of 30 subjects with Phelan-McDermid Syndrome (PMS), defining three distinct subsetsStudy provides clinical scales and thresholds for patient selection in future clinical trials, based on aggressiveness, cognition, and behavioral traitsConducted in collaboration with the Medical and Molecular Genetics Institute (INGEMM) and the Research Institute La Paz Hospital (IdiPaz) in Madrid MADRID and CAMBR
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"A non-interventional study published in Frontiers in Psychiatry","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Psychometric profile characterization of 30 subjects with Phelan-McDermid Syndrome (PMS), defining three distinct subsets","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Study provides clinical scales and thresholds for patient selection in future clinical trials, based on aggressiveness, cognition, and behavioral traits","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Conducted in collaboration with the Medical and Molecular Genetics Institute (INGEMM) and the Research Institute La Paz Hospital (IdiPaz) in Madrid","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":483,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the final results of an observational clinical study aimed at psychometrically characterizing individuals with Phelan-McDermid syndrome (PMS) carrying deletions or pathogenic variants in SHANK3 have been published online in the journal Frontiers in Psychiatry. The purpose of this study was to gather data that could serve as a foundation for a future precision psychiatry clinical trial involving vafidemstat for this patient population.","length":708,"tagName":"p"},{"type":"text","content":"Agitation and aggression are key components of PMS, and vafidemstat has demonstrated efficacy in reducing agitation and aggression in a basket trial involving patients with Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Di...